Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis

Wenchuan Zhou; Jinxin Tao; Xiaodong Zhou; Hongxia Chen

doi:10.1007/s13300-019-0624-4

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis

Diabetes Therapy ◽

10.1007/s13300-019-0624-4 ◽

2019 ◽

Vol 10 (3) ◽

pp. 835-852 ◽

Cited By ~ 3

Author(s):

Wenchuan Zhou ◽

Jinxin Tao ◽

Xiaodong Zhou ◽

Hongxia Chen

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Insulin Degludec ◽

Long Acting

Download Full-text

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1400011 ◽

2017 ◽

Vol 18 (17) ◽

pp. 1789-1798 ◽

Cited By ~ 14

Author(s):

Xiaoling Cai ◽

Xueying Gao ◽

Wenjia Yang ◽

Linong Ji

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Meta Analysis ◽

Insulin Degludec

Download Full-text

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

The Lancet ◽

10.1016/s0140-6736(10)62305-7 ◽

2011 ◽

Vol 377 (9769) ◽

pp. 924-931 ◽

Cited By ~ 89

Author(s):

Bernard Zinman ◽

Greg Fulcher ◽

Paturi V Rao ◽

Nihal Thomas ◽

Lars A Endahl ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Long Acting

Download Full-text

Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v3/review2 ◽

2020 ◽

Author(s):

CHARLES KHOURI

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v2/review2 ◽

2020 ◽

Author(s):

CHARLES KHOURI

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Author response for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v2/response1 ◽

2020 ◽

Author(s):

Philip Home ◽

Lawrence Blonde ◽

Sanjay Kalra ◽

Linong Ji ◽

Patricia Guyot ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Author Response ◽

Meal Time

Download Full-text

Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v2/review1 ◽

2020 ◽

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Decision letter for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v2/decision1 ◽

2020 ◽

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v1/review1 ◽

2020 ◽

Author(s):

CHARLES KHOURI

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial

Yearbook of Endocrinology ◽

10.1016/j.yend.2011.06.013 ◽

2011 ◽

Vol 2011 ◽

pp. 3-4

Author(s):

S. Schinner

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Long Acting

Download Full-text

Reduced Risk of Hypoglycemia with Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: Meta-Analysis of Five Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2012.07.399 ◽

2012 ◽

Vol 36 (5) ◽

pp. S57 ◽

Cited By ~ 2

Author(s):

Helena W. Rodbard ◽

Yehuda Handelsman ◽

Stephen Gough ◽

Jina Hahn ◽

Nathan Lassota ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text